Provides 2 to 3-fold higher efficacy in the presences of serum
No need to change tissue culture medium during transfection
Less toxic compared to commercial transfection reagents, leading to better retention of normal cellular physiology
Typical performance of All-Fect for transfecting cord-blood derived mesenchymal stem cells with a GFP plasmid. The study compared the performance of All-Fect against a leading lipofection reagent under conditions optimized for each reagent. The extent of transgene expression was quantitated by flow cytometry, based on the extent of EGFP expression in arbitrary units. Typical fluorescent micrographs showing GFP expression after transfection are provided on the top.
Provides 2 to 3-fold higher efficacy in the presences of serum
No need to change tissue culture medium during transfection
Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology
Transfecting bone marrow stromal cells with Prime-Fect. GFP expression was induced with a plasmid and analyzed by fluorescent microscopy 2 days after transfection. Cell-associated DNA is visualized with a red label (A). Transfecting breast cancer MDA-MB-231 and MCF-7 cells with siRNA using Prime-Fect. The expression levels of two target genes were analyzed by qPCR after delivery of control (scrambled) and gene-specific siRNAs (2 days after transfection) (B). Transfecting umbilical cord-derived mesenchymal stem cells with Prime-Fect. GFP expression was induced with a plasmid DNA and analyzed by fluorescent microscopy 2 days after transfection. (C) A leading polymeric transfection reagent and (D) Prime-Fect.>
Provides 2 to 3-fold higher efficacy in the presences of serum
No need to change tissue culture medium during transfection
Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology
Uptake of Leu-Fect/FAM-siRNA complexes in K562 cells in vitro (A) and in vivo K562 tumors (B). Typical performance of Leu-Fect for transfecting K562 chronic myeloid leukemia (CML) cells with a specific siRNA against Bcr-Abl. The study compared the performance of Leu-Fect against a leading lipofection reagent and branched PEI (PEI25; 25 kDa) under conditions optimized for each reagent. The extent of gene silencing was quantitated by qPCR (C). The functional outcome, in the form of inhibition of cell growth, was assessed by the MTT Assay and expressed relative to non-treated cells (D).
Provides 2 to 3-fold higher efficacy in the presences of usual transfection reagent
No need to change tissue culture medium during transfection
Less toxic compared to lipofection and polymeric reagents, leading to better protein yields from the transfected cells
Long term stability at room temperature
Typical performance of Trans-Booster reagent for transfecting suspension growing Jurkat cells (top). Transfections with a GFP plasmid and a GFP mRNA are conducted in Jurkat cells with and without Trans-Booster in the transfection formulation. A leading lipofection reagent was compared to the All-Fect transfection reagent from RJH Biosciences in this study. The extent of transgene expression was quantitated by flow cytometry and summarized as the mean GFP fluorescence in arbitrary units. Note that for both mRNA and plasmid DNA based GFP expression, Trans-Booster gave a significant increase in transfection efficiency.
Provides 2 to 7-fold higher efficacy in the presences of serum compared with lipofection reagents
No need to change tissue culture medium during transfection
Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology
Transfection of mRNA with mRNA-Fect in (A) attachment-dependent MCF-7, MDA-MB-436 and MDA-MB-231 cells and (B) suspension-growing K562 and THP-1 cells. An mRNA coding for a reporter protein (Green Fluorescent Protein, GFP) was used to assess the efficiency of mRNA expression. Typical GFP expression levels were visualized under fluorescent microscopy (top pictures). The expression levels were quantitated by flow cytometry 72 hours after transfection and summarized as the percentage of cells positive for GFP (bottom graphs). For comparison, a leading lipofection reagent was used according to the manufacturer’s instructions.
Provides 2 to 7-fold higher efficacy in the presences of serum compared with lipofection reagents
No need to change tissue culture medium during transfection
Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology
Figure 1. Left. Transfection of Jurkat T-cells and breast cancer MDA-MB-436 cells using CRISP-Fect. sgRNA/Cas9 complexes (RNP) were formulated with indicated transfection reagents and added to the cells for 24 hours. RNP uptake was followed by using FITC-labeled Cas9. The results are summarized as arbitrary fluorescence units, indicating the average amount of RNPs delivered per cell. Right. Transfection of Jurkat T-cells with RNPs formulated at different ratios of Cas9/sgRNA using CRISP-Fect. Lipofectamine 2000 and jetOptimus was used as commercial reference reagents in these studies.
RJH manufactures a variety of transfection agents for your R&D needs. Download our catalogue for a list of our products.
